Favorable Interim Data Presented for Tyme’s SM-88 Phase 2 Trial for Prostate Cancer Patients

Favorable Interim Data Presented for Tyme’s SM-88 Phase 2 Trial for Prostate Cancer Patients
Tyme Technologies‘ SM-88 reduced the levels of circulating cancer cells — an indicator of metastatic disease — in all prostate cancer patients treated in an ongoing Phase 2 trial, according to data revealed at the European Society for Medical Oncology (ESMO) 2017 Congress, in Madrid, Spain. The findings support the potential of SM-88 as a

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *